Effects of ipragliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the multicenter prospective intervention study.

BACKGROUND: Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. METHOD: This was an investigator-initiated multicenter prospective intervention study in which ipragliflozin (50 mg) was administered once daily and glycemic control, estimated glomerular filtration rate (eGFR) and adverse events were evaluated after 4, 12-108 weeks of treatment. RESULT: There were 407 cases subject to analysis. In the estimated glomerular filtration rate (eGFR) >/= 90 group and eGFR >/=60 /= 45 300 group, and the eGFR /= 90 group. CONCLUSIONS: Ipragliflozin lowers eGFR and corrects hyperfiltration in cases with high eGFR (eGFR >/=60). In cases with low eGFR (eGFR>/=30 <60), ipragliflozin has the possibility of increasing eGFR in cases with low eGFR and exerting a renoprotective effect.